NK-1 Drug Fills Motion Sickness Gap - Summary - MDSpire

NK-1 Drug Fills Motion Sickness Gap

Tradipitant demonstrates 50% to 70% risk reduction for vomiting incidence during motion exposure in phase 3 trials.

  • By

  • Kerri Miller

  • January 2, 2026

  • 3 min

Share

Objective:

To report the FDA approval of NEREUS (tradipitant) for the prevention of motion-induced vomiting in adults.

Key Findings:
  • In Motion Syros (n = 365), vomiting occurred in 18% to 20% of patients receiving tradipitant versus 44% receiving placebo.
  • In Motion Serifos (n = 316), vomiting rates ranged from 10% to 18% with tradipitant versus 38% with placebo.
  • Risk reductions of 50% to 70% were observed across studies.
  • Tradipitant showed a favorable safety profile with common adverse reactions including somnolence and fatigue.
Interpretation:

The approval of tradipitant marks a significant advancement in the treatment of motion sickness, providing a new option for patients who have limited success with existing therapies.

Limitations:
  • Safety and effectiveness have not been established in pediatric patients.
  • Use is cautioned in patients with severe renal or hepatic impairment.
Conclusion:

Tradipitant offers a novel therapeutic approach to motion sickness, leveraging modern neuropharmacology to improve patient outcomes.

Original Source(s)

NK-1 Drug Fills Motion Sickness Gap

  • by Kerri Miller

  • January 2, 2026

Related Content

Obesity’s Cancer Role Underestimated

A proposed framework highlights potential sources of bias in current estimates

Type 2 Diabetes Linked to SSNHL Risk

Mendelian randomization analysis shows independent association, with no link for type 1 diabetes, obesity, or hyperlipidemia.

FDA Grants Accelerated Approval for OTOF Gene Therapy

A one-time intracochlear gene therapy improved hearing outcomes in patients with OTOF-related sensorineural hearing loss in the phase 1/2 CHORD trial.